This background document (EUR/RC72/BG/7) was considered and adopted by the WHO Regional Committee for Europe at its 72nd session (Tel Aviv, Israel, 12–14 September 2022), together with the working document (EUR/RC72/7) and information document (EUR/RC72/INF./4). The Regiona...l Committee adopted resolution EUR/RC72/R3, in which it endorsed the framework.
more
Most of the global burden of sepsis occurs in low- and middle-income countries (LMICs), but the prevalence and etiology of sepsis in LMICs are not well understood. In particular, the lack of laboratory infrastructure in many LMICs has historically precluded an assessment of the pathogens leading to ...sepsis. A recent systematic review found that data describing antimicrobial resistance were absent for 43% of countries in Africa, and only two countries have national antimicrobial resistance plans. In addition, small studies have identified indiscriminate antibiotic use both in and out of hospital settings in sub-Saharan Africa. The absence of microbiological data and lack of antibiotic stewardship complicate sepsis management and almost certainly worsens outcomes, particularly in low-resource systems. The purpose of this study was to examine the prevalence, etiology, and outcomes of sepsis among a cohort of critically ill patients in a referral hospital of Malawi, with a focus on the prevalence of culture-confirmed bacteremia and urinary tract infections.
more
Cervical intraepithelial neoplasia (CIN) is a premalignant lesion that may exist at any one of three stages: CIN1, CIN2, or CIN3. If left untreated, CIN2 or CIN3 (collectively referred to as CIN2+) can progress to cervical cancer. Instead of screening and diagnosis by the standard sequence of cytolo...gy, colposcopy, biopsy, and histological confirmation of CIN, an alternative method is to use a ‘screen-and-treat’ approach in which the treatment decision is based on a screening test and treatment is provided soon or, ideally, immediately after a positive screening test. This guideline provides recommendations for strategies for a screen-and-treat programme
more
This Indicator-Based Pharmacovigilance Assessment Tool (IPAT) was developed as a comprehensive performance metric for pharmacovigilance and medicine safety systems.
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
A manual for people working in environments contaminated by landmines and other explosive hazards including improvised explosive devices.
Q5: What is the added advantage of doing an electroencephalography (EEG) in people with convulsive epilepsy in non- specialist settings in low and middle income countries?
Global Plan to end TB 2016-2020
Для создания этого отчета MSF исследовала программы и практику лечения лекарственно-чувствительного и лекарственно-устойчивого туберкулеза в восьмистранах с высо...ким бременем туберкулеза, обладающих различным набором эпидемиологических, экономических, географических и демографических характеристик (Бразилия, Зимбабве, Индия, Кения, Мьянма, Российская Федерация, Узбекистан, ЮАР). Мы исследовали ключевые показатели диагностики, лечения и доступности основных препаратов, поставок лекарственныхсредств и финансирования .
more
UNAIDS/WHO Working group
HIV/AIDS and STI surveillance 2015 / Reference
DOI:https://doi.org/10.1016/S2213-2600(20)30316-7
The Lancet Respiratory Medicine
In: Bonk M., Ulrichs T (eds). Global Health: Das Konzept der Globalen Gesundheit. Berlin: De Gruyter, 2021, pp. 523–556
Wohlstand, Gesundheit und Gesundheitsausgaben sind eng miteinander verknüpft. Im weltweiten Durchschnitt haben alle drei seit vielen Jahren stetig zugenommen. Im Vergleich hab...en Menschen in Ländern mit höheren Einkommen eine höhere Lebenserwartung. Die höchste Krankheitslast pro Mensch tritt in Ländern mit niedrigem Einkommen auf. Den größten Anteil an der gesamten globalen Krankheitslast haben Länder mit mittlerem Einkommen, in denen rund drei Viertel der Weltbevölkerung lebt. Im Mittel sind die Gesundheitsausgaben in Ländern mit höheren Einkommen insgesamt sowie pro Kopf höher als die Gesundheitsausgaben in Ländern mit niedrigeren Einkommen.
more